4/15
08:23 am
exas
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers [Yahoo! Finance]
Low
Report
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers [Yahoo! Finance]
4/14
06:17 am
exas
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups [Yahoo! Finance]
Low
Report
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups [Yahoo! Finance]
4/14
06:00 am
exas
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
Low
Report
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
4/11
10:39 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $60.00 price target on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $60.00 price target on the stock.
4/11
09:56 am
exas
Exact Sciences Co. (NASDAQ: EXAS) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) was upgraded by analysts at Mizuho to a "strong-buy" rating.
4/10
10:43 am
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Barclays PLC from $65.00 to $55.00. They now have an "overweight" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Barclays PLC from $65.00 to $55.00. They now have an "overweight" rating on the stock.
4/10
08:48 am
exas
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $60.00 price target on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $60.00 price target on the stock.
4/1
06:00 am
exas
Exact Sciences Schedules First Quarter 2025 Earnings Call
Low
Report
Exact Sciences Schedules First Quarter 2025 Earnings Call
3/31
06:11 am
exas
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening [Yahoo! Finance]
Low
Report
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening [Yahoo! Finance]
3/31
06:00 am
exas
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
Low
Report
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
3/28
08:02 am
exas
Exact Sciences Co. (NASDAQ: EXAS) was given a new $60.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) was given a new $60.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock.
3/21
08:09 pm
exas
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/20
10:19 am
exas
Katie Couric shares what she wishes she knew about colon cancer before her husband died at 42 years old [Business Insider]
Low
Report
Katie Couric shares what she wishes she knew about colon cancer before her husband died at 42 years old [Business Insider]
3/20
10:02 am
exas
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack [Yahoo! Finance]
Low
Report
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack [Yahoo! Finance]
3/20
09:46 am
exas
Colorectal Cancer Screening and Diagnostics Market Report 2025, with Profiles of Fujifilm, Olympus, Exact Sciences, Danaher, Guardant Health, Diacarta, Mainz Biomed, Novigenix and more [Yahoo! Finance]
Low
Report
Colorectal Cancer Screening and Diagnostics Market Report 2025, with Profiles of Fujifilm, Olympus, Exact Sciences, Danaher, Guardant Health, Diacarta, Mainz Biomed, Novigenix and more [Yahoo! Finance]
3/15
10:15 am
exas
HerHealth Oncology Congress 2025: A Landmark Event in Advancing Women's Cancer Care
Low
Report
HerHealth Oncology Congress 2025: A Landmark Event in Advancing Women's Cancer Care
3/13
10:55 am
exas
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner [Yahoo! Finance]
Low
Report
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner [Yahoo! Finance]
3/13
07:50 am
exas
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Royal Bank of Canada. They set a "sector perform" rating and a $52.00 price target on the stock.
Medium
Report
Exact Sciences Co. (NASDAQ: EXAS) is now covered by analysts at Royal Bank of Canada. They set a "sector perform" rating and a $52.00 price target on the stock.
3/12
09:00 am
exas
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
Low
Report
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
3/12
05:20 am
exas
New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency [Yahoo! Finance]
Low
Report
New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency [Yahoo! Finance]
3/11
08:50 am
exas
Sunbird Bio Appoints Vijay Parthasarathy, Ph.D., MBA, as Chief Product and Strategy Officer [Yahoo! Finance]
Low
Report
Sunbird Bio Appoints Vijay Parthasarathy, Ph.D., MBA, as Chief Product and Strategy Officer [Yahoo! Finance]
3/7
09:27 am
exas
3 Top Cancer Biotechs to Keep An Eye On in 2025 [Yahoo! Finance]
Low
Report
3 Top Cancer Biotechs to Keep An Eye On in 2025 [Yahoo! Finance]
2/26
07:08 pm
exas
Natera (NTRA) Q4 Earnings: What To Expect [Yahoo! Finance]
Low
Report
Natera (NTRA) Q4 Earnings: What To Expect [Yahoo! Finance]
2/26
01:31 pm
exas
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $75.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $75.00 to $70.00. They now have an "overweight" rating on the stock.
2/26
09:09 am
exas
Watchmaker Genomics Advances TAPS Commercialization with Achievement of Key Technology Transfer Milestone [Yahoo! Finance]
Low
Report
Watchmaker Genomics Advances TAPS Commercialization with Achievement of Key Technology Transfer Milestone [Yahoo! Finance]